SEC Form 4 · accession 0000899866-16-000373

ALEXION PHARMACEUTICALS, INC. · ALXN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Leonard Bell

Director

Period of report

Nov 4, 2016

Accepted (ET)

Nov 7, 2016 · 7:44 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000899866

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, par value $.0001 per share^F1	Nov 4, 2016	S	334	$139.90	D	404,621	I	By trust
Common Stock, par value $.0001 per share^F1	Nov 4, 2016	S	334	$144.90	D	404,287	I	By trust
Common Stock, par value $.0001 per share^F1	Nov 4, 2016	M	36,649	$22.90	A	440,936	D
Common Stock, par value $.0001 per share^F1	Nov 4, 2016	S	100	$136.00	D	440,836	D
Common Stock, par value $.0001 per share^F1,F2	Nov 4, 2016	S	2,600	$137.77	D	438,236	D
Common Stock, par value $.0001 per share^F1,F3	Nov 4, 2016	S	9,020	$139.05	D	429,216	D
Common Stock, par value $.0001 per share^F1,F4	Nov 4, 2016	S	11,838	$139.98	D	417,378	D
Common Stock, par value $.0001 per share^F1,F5	Nov 4, 2016	S	8,521	$140.83	D	408,857	D
Common Stock, par value $.0001 per share^F1,F6	Nov 4, 2016	S	831	$141.84	D	408,026	D
Common Stock, par value $.0001 per share^F1,F7	Nov 4, 2016	S	3,739	$145.06	D	404,287	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to Purchase Common Stock^F1	$22.90	Nov 4, 2016	M	36,649	D	Apr 28, 2010	Jan 28, 2020	Common Stock, par value $.0001 per share	36,649	116,001	D

Explanation of responses

F1The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
F2This transaction was executed in multiple trades through a broker-dealer at prices ranging from $137.27 - $138.27. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F3This transaction was executed in multiple trades through a broker-dealer at prices ranging from $138.38 - $139.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F4This transaction was executed in multiple trades through a broker-dealer at prices ranging from $139.44 - $140.44. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F5This transaction was executed in multiple trades through a broker-dealer at prices ranging from $140.44 - $141.44. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F6This transaction was executed in multiple trades through a broker-dealer at prices ranging from $141.66 - $142.66. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F7This transaction was executed in multiple trades through a broker-dealer at prices ranging from $144.90 - $145.90. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.